SATB2 and osteoporosis: Thus, the present study aimed to explore the role of miR-103 on the proliferation and osteogenic differentiation of HBMScs using gain- and lose-of-function assays, and to investigate the underlying molecular mechanism of miR-103 on SATB2. The findings suggested that miR-103 inhibits HBMScs proliferation and osteogenic differentiation by directly targeting SATB2, indicating regulation of miR-103 as a potential molecular therapeutic strategy for osteoporosis treatment.